Navigation Links
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
Date:11/20/2008

dical need for additional treatment options to combat resistant infections and is the first antibiotic in the dihydrofolate reductase (DHFR) selective inhibitor class to demonstrate efficacy against cSSSIs caused by MRSA. The DHFR class has been proven safe and effective in more than four decades of clinical use.

About Arpida

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the United States. It focuses on the discovery, development and commercialization of novel drugs for the treatment of microbial infections. Arpida has a fully integrated platform for the discovery and development of drug candidates to address the increasing prevalence of resistance of bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), to existing antibiotic therapies. Arpida is currently developing an iclaprim oral formulation as a step-down therapy after intravenous therapy. Apart from the flagship iclaprim program, Arpida has an innovative antifungal treatment in Phase III clinical development as well as several earlier-stage programs (AR-709 and AR-2474).

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

(i) Centers for Disease Control and Prevention Web site. Healthcare-Associated Methic
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
9. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  ANI Pharmaceuticals, ... announced that it has acquired the approved abbreviated ... USP 50mg, 100mg and 150mg, previously marketed by ... market for this product was approximately $39 million ... Przybyl , President and CEO of ANI Pharmaceuticals, ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Japan Pharma Outlook 2015: Year ... Overseas Strategic Initiatives" report to their offering. ... Japan from April -2014 (Annexure 1) ... the companies - whether generic or innovator. The most ...
(Date:3/5/2015)... -- Hitachi Medical Systems Europe is ... *    at ECR 2015 - the open high-field ... benchmark for patient-centric care. The new features of OASIS ... workflow management and costs. OASIS demonstrates the high levels ... in Neurology, Orthopaedics, Paediatrics, Oncology, Vascular and General Imaging, ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3
(Date:3/5/2015)... March 05, 2015 From Oct. 5-10, Mumbai, ... Textile Sustainability Conference . These dates include the following activities:, ... all Attendees , October 6: Conference Day 1, ... October 7: Conference Day 2, ending with Local Entertainment and ... Round Table and other Materials Meetings , October ...
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 ... of formaldehyde in low-cost laminate flooring products, ... leading manufacturer of eco-friendly building materials made primarily ... safety by testing all their flooring products for ... detection laboratory Benchmark International (BMH). Results ...
(Date:3/5/2015)... 05, 2015 Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ... heart attacks, strokes and other serious cardiovascular events due ... to move forward in the federal multidistrict litigation now ... According to a Case Management Order issued on March ... use of master pleadings in the proceeding. Among other ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The ... kinds of income to the Arizona economy each year, ... report, Demonstrating the Economic Value of Maricopa County Community ... of the Maricopa district in fiscal year 2013-2014. ... Specialists International (EMSI), an organization that specializes in ...
(Date:3/5/2015)... Auburn, CA (PRWEB) March 05, 2015 ... and clinical solutions for the population health management arena, ... recently enhanced case management software, ACUITY Advanced Careā„¢ (ACUITY) ... user interface, improved performance and the advantages of automation. ... 12:30 p.m. ET, will be led by Jeff Frater, ...
Breaking Medicine News(10 mins):Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3
... ... Sculptra@ trainer Dr Cheryl Effron of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ ... ... Cheryl Effron of Cosmetic Dermatology of Orange County offers Sculptra Aesthetic@ at affordable prices., ...
... , ... Box" Solution to the Abortion coverage debate within health reform is to have policyholders select ... not. , ... 2009 -- In response to Saturday’s near-derailment of comprehensive health reform over abortion coverage and ...
... WAVE ... exercise technology into South America, beginning in Argentina, Chile and Uruguay. All three of ... available in South America. , ... (Vocus) November 10, 2009 -- WAVE (Whole-Body Advanced Vibration Exercise), a North ...
... University Rollins School of Public Health researchers will present ... American Public Health Association,s annual meeting in Philadelphia, including ... a physician screen chest pain patients within 10 minutes ... Additional public health research findings from Emory scientists are ...
... , WASHINGTON, Nov. 9 Lung Cancer Alliance (LCA) ... Closing Bell for the New York Stock Exchange(TM) (NYSE) tomorrow ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , Five and a half year ... the end of the day,s trading by ringing The Closing ...
... The Churchill Centre today announced that it plans to bestow ... lifelong commitment to promoting democracy through progressive free market practices ... Marriott will receive his award at a ceremony and dinner ... Hotel. , "This is a testament to how Bill ...
Cached Medicine News:Health News:FDA-Approved Sculptra@ Now Offers by Orange County Dermatologist Dr. Cheryl Effron 2Health News:“Think Outside the Box” Blog Proposes Better Abortion Compromise for Health Reform 2Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2Health News:Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange(TM) 2Health News:J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership 2
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
The Diamedix immunosimplicity® Is- Rheumatoid Factor Test Kit is an EIA procedure intended for the quantitation of IgM antibodies to IgG antigen. The results are reported in IU/mL, traceable to t...
RFScan Latex Test Kit-100...
Medicine Products: